GlassScriptPhysician profile
Hari Madichetty
NPI 1437123585
$4,830.14
in general payments reported to CMS, 2019-2025
29 companies · $885 in 2025
The $885 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $616 · 2021: $865 · 2022: $560 · 2023: $638 · 2024: $764 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,286.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,130.94 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $880.30 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Grifols USA, LLC | $493.34 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.79 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Baxter Healthcare | $147.07 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $136.52 | 2020-2023 | Yupelri |
| Genzyme Corporation | $135.71 | 2019-2025 | |
| Verona Pharma, INC. | $125.41 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $87.31 | 2024-2025 | Inspire |
| Vapotherm INC | $87.29 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.33 | 2024-2025 | Glassia |
| Amgen INC. | $39.22 | 2025 | Tezspire |
| Dynavax Technologies Corporation | $32.73 | 2024 | Heplisav-B |
| Vifor Pharma, INC. | $29.92 | 2024 | Zemaira |
| Csl Behring | $24.46 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $24.41 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Shire North American Group INC | $20.88 | 2019 | |
| Ani Pharmaceuticals, INC. | $20.80 | 2024 | Purified Cortrophin Gel |
| Gilead Sciences, INC. | $20.69 | 2021 | |
| Viatris Specialty LLC | $20.58 | 2025 | Yupelri |
| Philips North America LLC | $19.08 | 2024 | (Ak6) Vest Therapy |
| Genentech USA, INC. | $19.01 | 2023 | Xolair |
| Regeneron Healthcare Solutions, INC. | $18.64 | 2019 | |
| Insmed, INC. | $17.33 | 2019 | |
| Advanced Respiratory, INC | $16.33 | 2020 | |
| Lilly USA, LLC | $14.68 | 2025 | Zepbound |
| Circassia INC. | $14.24 | 2019 | |
| Merck Sharp & Dohme LLC | $13.47 | 2022 | |
| Jazz Pharmaceuticals INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hari Madichetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.